The decision, which stems from a challenge by Bayer competitor OLLY PBC, offers a closer look at how NAD is evaluating implied claims in the increasingly competitive male fertility supplement segment.
Fertility positioning seen as implying conception outcomes
In addition to issues with express claims about the product, NAD examined the brand’s framing of pre-conception use and determined that the combination of timing guidance and product positioning may indicate outcomes beyond general nutritional support.
“The National Advertising Division (NAD) found that certain claims, including that men should take the product for at least three months before conception and that the product is specially designed to provide nutritional support while trying to conceive, reasonably convey the message that the product improves men’s chances of conception,” the division reported.
NAD reached a similar conclusion on sperm health messaging, notably within the context of fertility-focused marketing. “In the fertility-focused context, certain claims that the product supports healthy sperm reasonably convey the message that the product improves sperm health and viability,” NAD wrote its case decision.
Ingredient claims and antioxidant messaging under review
Beyond fertility positioning, NAD also examined how Bayer presented specific nutrients and antioxidant activity in the product.
The claim that the formula includes “powerful antioxidants” tied to sperm health drew particular scrutiny, with NAD assessing both the strength of the antioxidant characterization and the role attributed to individual ingredients.
“This claim conveys the message that the identified nutrients are responsible for delivering the claimed sperm-related benefits and that lycopene exhibits powerful antioxidant activity in the product,” the division reported.
NAD concluded that the available evidence did not substantiate those messages and recommended changes to avoid conveying unsupported ingredient-level benefits.
‘Complete multivitamin’ claim not challenged
NAD did not recommend changes to Bayer’s use of the term “complete multivitamin,” citing a lack of evidence showing consumer confusion tied to the product name.
“With respect to Bayer’s use of the term ‘complete multivitamin,’ NAD concluded that, in the absence of extrinsic evidence demonstrating consumer confusion caused by the product name, it would not recommend a change to the product name,” the division reported.
Industry perspective: Wider context shaping claim interpretation
The case shows a continued shift toward evaluating claims in the context of how products are marketed and used, according to Jennifer Adams, Partner at Amin Wasserman Gurnani, LLP.
“NAD has increasingly given the overall advertising context greater weight when examining what would be considered standard structure/function claims,” Adams told NutraIngredients.
In this case, she pointed to how usage instructions and lifecycle positioning contributed to the implied message. “Here, NAD considered the positioning (specifically for at least 3 months before conception) and directions for use (to switch to a different product after conception) as causing the claims to imply a benefit beyond general nutrition support, specifically that the product improves the likelihood of conception,” she said. She also noted that NAD does not always rely on consumer perception evidence to reach those conclusions.
Noting an overall recent increase in NAD scrutiny in the supplement space in recent months, Adams further cautioned that “companies should be sure to holistically consider overall product context, and not just surrounding claims, for an unintended implied messages – because NAD is certainly doing so."
Company responses
In response to NI’s request for comment, Bayer pointed to its statement included in its response to NAD.
“Bayer agrees to comply with NAD’s decision,” the company said, but pushed back on the finding that its messaging implies conception-related benefits.
“Bayer strongly disagrees, however, that its advertising conveys a benefit beyond supporting a normal structure or function of the body,” the company added, describing its positioning as “limited to neutral and straightforward language that its multivitamin provides ingredients known to play a role in sperm health.”
Bayer also highlighted what it characterized as key distinctions in the decision, particularly around substantiation standards.
“Bayer is pleased that NAD reaffirmed its distinction between ‘support’ claims and performance claims and acknowledged that population intake data may support the general nutritional relevance of an ingredient, whereas performance claims require outcome-appropriate evidence,” the company said.
The organization further noted that NAD did not recommend changes to the product name.
OLLY PBC did not respond to a request for comment by press time.
